Douglas Stairs, PhD - Penn State Cancer Institute
Researcher Profile
Douglas Stairs, PhD
Associate Professor, Department of Pathology and Laboratory Medicine
Division of Experimental Pathology
Associate Professor, Department of Pharmacology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Division of Experimental Pathology
Associate Professor, Department of Pharmacology
Center for Cannabis and Natural Product Pharmaceuticals (CCNPP)
Scientific Program:Next-Generation Therapies
Research Interests
The worldwide prevalence of esophageal cancer varies greatly, with the highest rates found in Asia. In the United States, the two most common types of esophageal cancers are squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Since patients are typically diagnosed at a late stage of the disease, overall five-year survival is approximately 18 percent. Given the poor survival rate, the advanced stage of the disease at diagnosis and the increasing frequency of ESCC (worldwide) and EAC (U.S.), it is increasingly important to understand the molecular mechanisms of initiation of these tumors as well as the genes and pathways involved, which is what Dr. Douglas Stairs' work focuses on.
- Neoplasms
- delta catenin
- Epithelium
- Barrett Esophagus
- Esophageal Squamous Cell Carcinoma
- Down-Regulation
- Keratinocytes
- Genes
- Human Mammary Glands
- Breast
- ErbB Receptors
- Proteins
Recent Publications
2024
Alden, NA, Yeingst, TJ, Pfeiffer, HM, Celik, N, Arrizabalaga, JH, Helton, AM, Liu, Y, Stairs, DB, Glick, AB, Goyal, N & Hayes, DJ 2024, 'Near-Infrared Induced miR-34a Delivery from Nanoparticles in Esophageal Cancer Treatment', Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303593
2022
Chalmers, FE, Mogre, S, Rimal, B, Son, J, Patterson, AD, Stairs, DB & Glick, AB 2022, 'The unfolded protein response gene Ire1α is required for tissue renewal and normal differentiation in the mouse tongue and esophagus', Developmental biology, vol. 492, pp. 59-70. https://doi.org/10.1016/j.ydbio.2022.09.009
2021
Stairs, DB, Landmesser, ME, Aliaga, C, Chen, KM, Sun, YW & El-Bayoumy, K 2021, 'Black raspberry restores the expression of the tumor suppressor p120ctn in the oral cavity of mice treated with the carcinogen dibenzo[a,l] pyrene diol epoxide', PloS one, vol. 16, no. 11 November, e0259998. https://doi.org/10.1371/journal.pone.0259998
Teye, EK, Lu, S, Chen, F, Yang, W, Abraham, T, Stairs, DB, Wang, HG, Yochum, GS, Brodsky, RA & Pu, JJ 2021, 'PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression', Scientific reports, vol. 11, no. 1, 19022. https://doi.org/10.1038/s41598-021-98218-y
2020
El-Bayoumy, K, Christensen, ND, Hu, J, Viscidi, R, Stairs, DB, Walter, V, Chen, KM, Sun, YW, Muscat, JE & Richie, JP 2020, 'An integrated approach for preventing oral cavity and oropharyngeal cancers: Two etiologies with distinct and shared mechanisms of carcinogenesis', Cancer Prevention Research, vol. 13, no. 8, pp. 649-660. https://doi.org/10.1158/1940-6207.CAPR-20-0096
Landmesser, ME, Raup-Konsavage, WM, Lehman, HL & Stairs, DB 2020, 'Loss of p120ctn causes EGFR-targeted therapy resistance and failure', PloS one, vol. 15, no. 10 October, e0241299. https://doi.org/10.1371/journal.pone.0241299
Christensen, ND, Chen, KM, Hu, J, Stairs, DB, Sun, YW, Aliaga, C, Balogh, KK, Atkins, H, Shearer, D, Li, J, Brendle, SA, Gowda, K, Amin, S, Walter, V, Viscidi, R & El-Bayoumy, K 2021, 'The environmental pollutant and tobacco smoke constituent dibenzo[def,p]chrysene is a co-factor for malignant progression of mouse oral papillomavirus infections', Chemico-Biological Interactions, vol. 333, 109321. https://doi.org/10.1016/j.cbi.2020.109321
Lehman, HL, Kidacki, M & Stairs, DB 2020, 'Twist2 is NFkB-responsive when p120-catenin is inactivated and EGFR is overexpressed in esophageal keratinocytes', Scientific reports, vol. 10, no. 1, 18829. https://doi.org/10.1038/s41598-020-75866-0